Effect of Femoropopliteal Stent Fracture on Patency Studied

 

July 20, 2009—In the Journal of the American College of Cardiology: Cardiovascular Interventions, Osamu Iida, MD, et al published findings from their investigation of the time course of stent patency in the femoropopliteal artery for as long as 4 years (2009;2:665–671). The investigators noted that stent fracture has been related to poor 2-year patency in the femoropopliteal artery.

According to the investigators, they studied 239 consecutive patients who underwent provisional de novo stenting with nitinol stents for 333 limbs (Luminexx stent [Bard Peripheral Vascular, Inc., Tempe, AZ] in 91 limbs; Smart stent [Cordis Corporation, Bridgewater, NJ] in 242 limbs) from April 2004 to December 2007. Stent fracture was determined by x-ray with multiple projections. Patency was assessed by Duplex ultrasonography as peak systolic velocity ratio < 2.4 or by angiography (% diameter stenosis < 50%). Primary patency in patients with and without stent fracture at follow-up was assessed along with factors influencing stent fracture.

The investigators reported that primary patency was 81%, 74%, 68%, and 65% at 1, 2, 3, and 4 years, respectively. Stent fracture occurred in 14% (78 of 544) of stents and 17% (55 of 333) of limbs. Stent fracture was significantly associated with multiple stent deployments (with fracture, 2.3 ± 0.9 stents vs without fracture, 1.5 ± 0.7 stents; P < .001) and long lesions (with fracture, 208 ± 84 mm vs without fracture, 121 ± 79 mm; P < .001). Primary patency was 68% with fracture versus 83% without fracture at 1 year (P = .03); 65% versus 75% at 2 years (P = .05); 61% versus 69% at 3 years (P = .06); and 61% versus 65% at 4 years (P = .07). Neither type 1 nor type 3 fracture affected patency, although type 2 showed the worst patency.

The investigators concluded that stent fracture worsened the patency during the first 2 years, but it apparently did not affect patency beyond 2 years. In particular, complete stent separation did not affect patency.
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.